Back to top

Xencor Earns Buy Rating as XmAb541 and XmAb808 Advance Toward Differentiated Solid-Tumor Franchise

William Blair analyst Matt Phipps has maintained their bullish stance on XNCR stock, giving a Buy rating on July 30. Matt Phipps has given his Buy ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Xencor, Inc. (XNCR)